HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

OPEN ACCESS ARTICLE

This Article Free via Open Access: OA OA Full Text Full Text (PDF) OA All Versions of this Article: 2005-0324v1 23/10/1454    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lo, B. Articles by Yamamoto, K. R. Search for Related Content PubMed Articles by Lo, B. Articles by Yamamoto, K. R.

ORIGINAL ARTICLE-CHARACTERIZATION SERIES

A New Era in the Ethics of Human Embryonic Stem Cell Research

^a Program in Medical Ethics and Division of General Internal Medicine in the
^b Department of Medicine and Department of Obstetrics, Gynecology, and Reproductive Sciences;
^c Program in Development and Stem Cell Biology and Department of Neurology at the University of California San Francisco, San Francisco, California, USA;
^d School of Law at Santa Clara University, Santa Clara, California, USA;
^e Program in Human Embryonic Stem Cell Biology;
^f Human Subjects Protection Program;
^g Community member of the UCSF Committee on Gamete, Embryo, and Stem Cell Research, San Francisco, California, USA;
^h Department of Cellular and Molecular Pharmacology at the University of California San Francisco, San Francisco, California, USA

Key Words. Human stem cells • Ethics • Consent

Correspondence: Bernard Lo, M.D., Room C 126, 521 Parnassus Avenue, San Francisco, California 94143-0903, USA. Telephone: 415-476-5370; Fax: 415-476-5020; e-mail: bernie{at}medicine.ucsf.edu

Scientific progress in human embryonic stem cell (hESC) research and increased funding make it imperative to look ahead to the ethical issues generated by the expected use of hESCs for transplantation. Several issues should be addressed now, even though phase I clinical trials of hESC transplantation are still in the future. To minimize the risk of hESC transplantation, donors of materials used to derive hESC lines will need to be recontacted to update their medical history and screening. Because of privacy concerns, such recontact needs to be discussed and agreed to at the time of donation, before new hESC lines are derived. Informed consent for phase I clinical trials of hESC transplantation also raises ethical concerns. In previous phase I trials of highly innovative interventions, allegations that trial participants had not really understood the risk and benefits caused delays in subsequent trials. Thus, researchers should consider what information needs to be discussed during the consent process for hESC clinical trials and how to verify that participants have a realistic understanding of the study. Lack of attention to the special ethical concerns raised by clinical trials of hESC transplantation and their implications for the derivation of new hESC lines may undermine or delay progress toward stem cell therapies.

This article has been cited by other articles:

				B. Lo, A. Kriegstein, and D. Grady Clinical trials in stem cell transplantation: guidelines for scientific and ethical review Clinical Trials, October 1, 2008; 5(5): 517 - 522. [Abstract] [PDF]